Mitochondrial morphology is associated with respiratory chain uncoupling in autism spectrum disorder

Richard E Frye, Loïc Lionnard, Indrapal Singh, Mohammad A Karim, Hanane Chajra, Mathilde Frechet, Karima Kissa, Victor Racine, Amrit Ammanamanchi, Patrick John McCarty, Leanna Delhey, Marie Tippett, Shannon Rose, Abdel Aouacheria, Richard E Frye, Loïc Lionnard, Indrapal Singh, Mohammad A Karim, Hanane Chajra, Mathilde Frechet, Karima Kissa, Victor Racine, Amrit Ammanamanchi, Patrick John McCarty, Leanna Delhey, Marie Tippett, Shannon Rose, Abdel Aouacheria

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is associated with unique changes in mitochondrial metabolism, including elevated respiration rates and morphological alterations. We examined electron transport chain (ETC) complex activity in fibroblasts derived from 18 children with ASD as well as mitochondrial morphology measurements in fibroblasts derived from the ASD participants and four typically developing controls. In ASD participants, symptoms severity was measured by the Social Responsiveness Scale and Aberrant Behavior Checklist. Mixed-model regression demonstrated that alterations in mitochondrial morphology were associated with both ETC Complex I+III and IV activity as well as the difference between ETC Complex I+III and IV activity. The subgroup of ASD participants with relative elevation in Complex IV activity demonstrated more typical mitochondrial morphology and milder ASD related symptoms. This study is limited by sample size given the invasive nature of obtaining fibroblasts from children. Furthermore, since mitochondrial function is heterogenous across tissues, the result may be specific to fibroblast respiration. Previous studies have separately described elevated ETC Complex IV activity and changes in mitochondrial morphology in cells derived from children with ASD but this is the first study to link these two findings in mitochondrial metabolism. The association between a difference in ETC complex I+III and IV activity and normal morphology suggests that mitochondrial in individuals with ASD may require ETC uncoupling to function optimally. Further studies should assess the molecular mechanisms behind these unique metabolic changes.Trial registration: Protocols used in this study were registered in clinicaltrials.gov as NCT02000284 and NCT02003170.

Conflict of interest statement

The authors R.E.F., I.S., M.A.K., A.A., L.L., H.C., M.F., K.K., V.R., P.J.M., L.D., M.T., and S.R. declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. The MITOTOUCH® algorithm was registered to the APP, the French Software registration agency.

© 2021. The Author(s).

Figures

Fig. 1. Process for obtaining mitochondrial morphology…
Fig. 1. Process for obtaining mitochondrial morphology parameters.
MITOTOUCH® proprietary software identifies mitochondrial clusters, skeletonizes the clusters and divides them into individual mitochondria to derive both cluster and isolated mitochondrial metrics at the single cell level.
Fig. 2. Electronic transport chain activity of…
Fig. 2. Electronic transport chain activity of autism spectrum disorder fibroblast cell lines.
Standardized mitochondrial enzyme activity from 18 ASD fibroblasts represented in (A) linear graph and (B) radar plot. Green box represents normative range (±1.96 SD). ETC = Electron transport chain; CS = Citrate Synthase.
Fig. 3. Relationship between mitochondrial respiration and…
Fig. 3. Relationship between mitochondrial respiration and morphology in autism spectrum disorder fibroblast cell line.
Examples of the relationship between mitochondrial morphological parameters and mitochondrial ETC complex activity for fibroblasts derived from children with ASD. Individual morphological measurements from each cell examined are depicted.
Fig. 4. Images of mitochondrial morphology in…
Fig. 4. Images of mitochondrial morphology in fibroblast cell lines.
Fibroblasts from patients with (A, B) autism spectrum disorder or from (C) control individuals. Mitochondria are highlighted in red, the cell membrane in green and nuclei in blue. A Top panels: fibroblasts from three ASD patients with relatively increased Electron Transport Chain Complex IV activity. B Middle Panels: fibroblasts from three individuals with autism spectrum disorder with roughly similar Electron Transport Chain Complex I+III RS and Complex IV activity. C Bottom Panels: fibroblasts from three control individuals. Scale bar: 15 µm. In each case, the inset is a ×2 magnification of a region-of-interest (indicated by a white box) showing the mitochondrial compartment. Consistent with the morphological measurements, mitochondria present in cells from ASD patients with relatively increased Electron Transport Chain Complex IV activity are found in larger cells and tend to be more abundant, more clustered and more branched. In contrast, mitochondria present in cells from ASD patients with relatively similar Electron Transport Chain Complex I+III RS and Complex IV activity tend to form more compact clusters of less complex geometry and appear to be more uniformly distributed throughout smaller cells.
Fig. 5. Radar-chart distribution of normalized morphological…
Fig. 5. Radar-chart distribution of normalized morphological features obtained for representative fibroblasts from patients with autism spectrum disorder or from control individuals.
Three representative microscopic fields are shown that correspond to control fibroblasts (GM01651), ASD fibroblasts with elevated Complex IV activity relative to Complex I+III (AMC163) and ASD fibroblasts with relatively equal Complex IV and I+III activities (AMC565). The segmented images (top panels) were randomly colorized for illustrative purposes. Parameter values Vp (expressed as arbitrary units) were obtained using the MITOTOUCH® software. Minimum value (Vmin) and maximum value (Vmax) were derived for each parameter based on the entire data set. Values Vp were normalized (to give Vn) by applying the following formula: Vn = (Vp – Vmin)/(Vmax – Vmin) and Vn values were reported on the radar chart (bottom panel). Fibroblasts with relatively increased Complex IV activity (green line) have their morphological feature space more similar to that of control fibroblasts (orange) (for 29 parameters out of 31) whereas the morphological feature space of fibroblasts with relatively equal ETC Complex I+III and IV activities (blue) appear to be slightly distant.
Fig. 6. The relationship between ASD symptoms…
Fig. 6. The relationship between ASD symptoms and behaviors for mitochondrial cluster roundness.
Both (B) social withdrawal and (C) stereotyped movements on the aberrant behavior checklist (ABC) were significantly worse with increased mitochondrial cluster roundness.
Fig. 7. The relationship between ASD symptoms…
Fig. 7. The relationship between ASD symptoms and behaviors for mitochondrial cluster perimeter.
Both (B) Social Withdrawal and (C) Stereotyped Movements on the Aberrant Behavior Checklist (ABC) were significantly better with higher mitochondrial cluster perimeter.
Fig. 8. The Discriminant Function developed from…
Fig. 8. The Discriminant Function developed from scales of ASD symptoms and behavior.
A Function separates ASD individuals into the two mitochondrial activity subgroups. B Loadings (influence) of individual ASD symptom and behavior scales.

References

    1. Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®). 5th edn. Washington, DC: American Psychiatric Association Publishing; 2013.
    1. McCarty P, Frye RE. Early detection and diagnosis of autism spectrum disorder: why is it so difficult? Semin Pediatr Neurol. 2020;35:100831. doi: 10.1016/j.spen.2020.100831.
    1. Maenner MJ, Shaw KA, Baio J, Washington A, Washington A, Patrick M, et al. Prevalence of autism spectrum disorder among children aged 8 years—autism and developmental disabilities monitoring network, 11 sites, United States, 2016. MMWR Surveill Summ. 2020;69:1–12. doi: 10.15585/mmwr.ss6904a1.
    1. Schaefer GB, Mendelsohn NJ, Professional P, Guidelines C. Clinical genetics evaluation in identifying the etiology of autism spectrum disorders: 2013 guideline revisions. Genet Med. 2013;15:399–407. doi: 10.1038/gim.2013.32.
    1. O'roak BJ, Stessman HA, Boyle EA, Witherspoon KT, Martin B, Lee C, et al. Recurrent de novo mutations implicate novel genes underlying simplex autism risk. Nat Commun. 2014;5:5595. doi: 10.1038/ncomms6595.
    1. Wang L, Zhang Y, Li K, Wang Z, Wang X, Li B, et al. Functional relationships between recessive inherited genes and genes with de novo variants in autism spectrum disorder. Mol Autism. 2020;11:75. doi: 10.1186/s13229-020-00382-x.
    1. Tammimies K, Marshall CR, Walker S, Kaur G, Thiruvahindrapuram B, Lionel AC, et al. Molecular diagnostic yield of chromosomal microarray analysis and whole-exome sequencing in children with autism spectrum disorder. JAMA. 2015;314:895–903. doi: 10.1001/jama.2015.10078.
    1. Yuen RK, Thiruvahindrapuram B, Merico D, Walker S, Tammimies K, Hoang N, et al. Whole-genome sequencing of quartet families with autism spectrum disorder. Nat Med. 2015;21:185–91. doi: 10.1038/nm.3792.
    1. Rossignol DA, Genuis SJ, Frye RE. Environmental toxicants and autism spectrum disorders: a systematic review. Transl Psychiatry. 2014;4:e360. doi: 10.1038/tp.2014.4.
    1. Frye RE, Cakir J, Rose S, Palmer RF, Austin C, Curtin P. Physiological mediators of prenatal environmental influences in autism spectrum disorder. Bioessays. 2021;43:e2000307. doi: 10.1002/bies.202000307.
    1. Hallmayer J, Cleveland S, Torres A, Phillips J, Cohen B, Torigoe T, et al. Genetic heritability and shared environmental factors among twin pairs with autism. Arch Gen Psychiatry. 2011;68:1095–102. doi: 10.1001/archgenpsychiatry.2011.76.
    1. Sandin S, Lichtenstein P, Kuja-Halkola R, Larsson H, Hultman CM, Reichenberg A. The familial risk of autism. JAMA. 2014;311:1770–7. doi: 10.1001/jama.2014.4144.
    1. Frye RE, Slattery JC, Quadros EV. Folate metabolism abnormalities in autism: potential biomarkers. Biomark Med. 2017;11:687–99. doi: 10.2217/bmm-2017-0109.
    1. James SJ, Melnyk S, Jernigan S, Cleves MA, Halsted CH, Wong DH, et al. Metabolic endophenotype and related genotypes are associated with oxidative stress in children with autism. Am J Med Genet B: Neuropsychiatr Genet. 2006;141B:947–56. doi: 10.1002/ajmg.b.30366.
    1. James SJ, Melnyk S, Jernigan S, Pavliv O, Trusty T, Lehman S, et al. A functional polymorphism in the reduced folate carrier gene and DNA hypomethylation in mothers of children with autism. Am J Med Genet B: Neuropsychiatr Genet. 2010;153B:1209–20.
    1. Sequeira JM, Desai A, Berrocal-Zaragoza MI, Murphy MM, Fernandez-Ballart JD, Quadros EV. Exposure to folate receptor alpha antibodies during gestation and weaning leads to severe behavioral deficits in rats: a pilot study. PLoS ONE. 2016;11:e0152249. doi: 10.1371/journal.pone.0152249.
    1. Frye RE, Cakir J, Rose S, Palmer RF, Austin C, Curtin P, et al. Mitochondria may mediate prenatal environmental influences in autism spectrum disorder. J Personalized Med. 2021;11:218. doi: 10.3390/jpm11030218.
    1. Frye RE, Cakir J, Rose S, Delhey L, Bennuri SC, Tippett M, et al. Prenatal air pollution influences neurodevelopment and behavior in autism spectrum disorder by modulating mitochondrial physiology. Mol Psychiatry. 2021;26:1561–77. doi: 10.1038/s41380-020-00885-2.
    1. Frye RE, Cakir J, Rose S, Delhey L, Bennuri SC, Tippett M, et al. Early life metal exposure dysregulates cellular bioenergetics in children with regressive autism spectrum disorder. Transl Psychiatry. 2020;10:223. doi: 10.1038/s41398-020-00905-3.
    1. Curtin P, Austin C, Curtin A, Gennings C, Arora M, et al. Dynamical features in fetal and postnatal zinc-copper metabolic cycles predict the emergence of autism spectrum disorder. Sci Adv. 2018;4:eaat1293. doi: 10.1126/sciadv.aat1293.
    1. Nunnari J, Suomalainen A. Mitochondria: in sickness and in health. Cell. 2012;148:1145–59. doi: 10.1016/j.cell.2012.02.035.
    1. Bornstein R, Gonzalez B, Johnson SC. Mitochondrial pathways in human health and aging. Mitochondrion. 2020;54:72–84. doi: 10.1016/j.mito.2020.07.007.
    1. Cabral-Costa JV, Kowaltowski AJ. Neurological disorders and mitochondria. Mol Asp Med. 2020;71:100826. doi: 10.1016/j.mam.2019.10.003.
    1. Rossignol DA, Frye RE. Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17:290–314. doi: 10.1038/mp.2010.136.
    1. Frye RE. Biomarkers of abnormal energy metabolism in children with autism spectrum disorder. N. Am J Med Sci. 2012;5:141–7. doi: 10.7156/v5i3p141.
    1. Giulivi C, Zhang YF, Omanska-Klusek A, Ross-Inta C, Wong S, Hertz-Picciotto I, et al. Mitochondrial dysfunction in autism. JAMA. 2010;304:2389–96. doi: 10.1001/jama.2010.1706.
    1. Napoli E, Wong S, Hertz-Picciotto I, Giulivi C. Deficits in bioenergetics and impaired immune response in granulocytes from children with autism. Pediatrics. 2014;133:e1405–1410. doi: 10.1542/peds.2013-1545.
    1. Weissman JR, Kelley RI, Bauman ML, Cohen BH, Murray KF, Mitchell RL, et al. Mitochondrial disease in autism spectrum disorder patients: a cohort analysis. PLoS ONE. 2008;3:e3815. doi: 10.1371/journal.pone.0003815.
    1. Frye RE, Rossignol DA. Mitochondrial dysfunction can connect the diverse medical symptoms associated with autism spectrum disorders. Pediatr Res. 2011;69:41R–47R. doi: 10.1203/PDR.0b013e318212f16b.
    1. Shoffner J, Hyams L, Langley GN, Cossette S, Mylacraine L, Dale J, et al. Fever plus mitochondrial disease could be risk factors for autistic regression. J Child Neurol. 2010;25:429–34. doi: 10.1177/0883073809342128.
    1. Singh K, Singh IN, Diggins E, Connors SL, Karim MA, Lee D, et al. Developmental regression and mitochondrial function in children with autism. Ann Clin Transl Neurol. 2020;7:683–94. doi: 10.1002/acn3.51034.
    1. Frye RE, Naviaux RK. Autistic disorder with complex IV overactivity: a new mitochondrial syndrome. J Pediatr Neurol. 2011;9:427–34.
    1. Frye RE, Melnyk S, Macfabe DF. Unique acyl-carnitine profiles are potential biomarkers for acquired mitochondrial disease in autism spectrum disorder. Transl Psychiatry. 2013;3:e220. doi: 10.1038/tp.2012.143.
    1. Frye RE, Cox D, Slattery J, Tippett M, Kahler S, Granpeesheh D, et al. Mitochondrial Dysfunction may explain symptom variation in Phelan-McDermid Syndrome. Sci Rep. 2016;6:19544. doi: 10.1038/srep19544.
    1. Palmieri L, Papaleo V, Porcelli V, Scarcia P, Gaita L, Sacco R, et al. Altered calcium homeostasis in autism-spectrum disorders: evidence from biochemical and genetic studies of the mitochondrial aspartate/glutamate carrier AGC1. Mol Psychiatry. 2010;15:38–52. doi: 10.1038/mp.2008.63.
    1. Hassan H, Gnaiger E, Zakaria F, Makpol S, Karim NA. Alterations in mitochondrial respiratiory capacity and membrane potential: a link between mitochondrial dysregulation and autism. MitoFit Preprint Arch. 2020;3:1–14.
    1. Frye RE, Rose S, Wynne R, Bennuri SC, Blossom S, Gilbert KM, et al. Oxidative stress challenge uncovers trichloroacetaldehyde hydrate-induced mitoplasticity in autistic and control lymphoblastoid cell lines. Sci Rep. 2017;7:4478. doi: 10.1038/s41598-017-04821-3.
    1. Rose S, Frye RE, Slattery J, Wynne R, Tippett M, Melnyk S, et al. Oxidative stress induces mitochondrial dysfunction in a subset of autistic lymphoblastoid cell lines. Transl Psychiatry. 2015;5:e526. doi: 10.1038/tp.2015.29.
    1. Rose S, Frye RE, Slattery J, Wynne R, Tippett M, Pavliv O, et al. Oxidative stress induces mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines in a well-matched case control cohort. PLoS ONE. 2014;9:e85436. doi: 10.1371/journal.pone.0085436.
    1. Rose S, Wynne R, Frye RE, Melnyk S, James SJ. Increased susceptibility to ethylmercury-induced mitochondrial dysfunction in a subset of autism lymphoblastoid cell lines. J Toxicol. 2015;2015:573701. doi: 10.1155/2015/573701.
    1. Bennuri SC, Rose S, Frye RE. Mitochondrial dysfunction is inducible in lymphoblastoid cell lines from children with autism and may involve the TORC1 pathway. Front Psychiatry. 2019;10:269. doi: 10.3389/fpsyt.2019.00269.
    1. Rose S, Bennuri SC, Davis JE, Wynne R, Slattery JC, Tippett M, et al. Butyrate enhances mitochondrial function during oxidative stress in cell lines from boys with autism. Transl Psychiatry. 2018;8:42. doi: 10.1038/s41398-017-0089-z.
    1. Rose S, Bennuri SC, Wynne R, Melnyk S, James SJ, Frye RE. Mitochondrial and redox abnormalities in autism lymphoblastoid cells: a sibling control study. FASEB J. 2017;31:904–9. doi: 10.1096/fj.201601004R.
    1. Delhey L, Kilinc EN, Yin L, Slattery J, Tippett M, Wynne R, et al. Bioenergetic variation is related to autism symptomatology. Metab Brain Dis. 2017;32:2021–31. doi: 10.1007/s11011-017-0087-0.
    1. Goldenthal MJ, Damle S, Sheth S, Shah N, Melvin J, Jethva R, et al. Mitochondrial enzyme dysfunction in autism spectrum disorders; a novel biomarker revealed from buccal swab analysis. Biomark Med. 2015;9:957–65. doi: 10.2217/bmm.15.72.
    1. Legido A, Jethva R, Goldenthal MJ. Mitochondrial dysfunction in autism. Semin Pediatr Neurol. 2013;20:163–75. doi: 10.1016/j.spen.2013.10.008.
    1. Pecorelli A, Ferrara F, Messano N, Cordone V, Schiavone ML, Cervellati F, et al. Alterations of mitochondrial bioenergetics, dynamics, and morphology support the theory of oxidative damage involvement in autism spectrum disorder. FASEB J. 2020;34:6521–38. doi: 10.1096/fj.201902677R.
    1. Fealy CE, Grevendonk L, Hoeks J, Hesselink MKC. Skeletal muscle mitochondrial network dynamics in metabolic disorders and aging. Trends Mol Med. 2021;S1471–4914:00198-2.
    1. Leduc-Gaudet JP, Hussain SNA, Barreiro E, Gouspillou G. Mitochondrial dynamics and mitophagy in skeletal muscle health and aging. Int J Mol Sci. 2021;22:8179.. doi: 10.3390/ijms22158179.
    1. Saxton WM, Hollenbeck PJ. The axonal transport of mitochondria. J Cell Sci. 2012;125:2095–104.
    1. Aouacheria A, Baghdiguian S, Lamb HM, Huska JD, Pineda FJ, Hardwick JM. Connecting mitochondrial dynamics and life-or-death events via Bcl-2 family proteins. Neurochem Int. 2017;109:141–61. doi: 10.1016/j.neuint.2017.04.009.
    1. Duvekot J, van der Ende J, Verhulst FC, Greaves-Lord K. The screening accuracy of the parent and teacher-reported Social Responsiveness Scale (SRS): comparison with the 3Di and ADOS. J Autism Dev Disord. 2015;45:1658–72. doi: 10.1007/s10803-014-2323-3.
    1. Murray MJ, Mayes SD, Smith LA. Brief report: excellent agreement between two brief autism scales (Checklist for Autism Spectrum Disorder and Social Responsiveness Scale) completed independently by parents and the Autism Diagnostic Interview-Revised. J Autism Dev Disord. 2011;41:1586–90. doi: 10.1007/s10803-011-1178-0.
    1. Bolte S, Westerwald E, Holtmann M, Freitag C, Poustka F. Autistic traits and autism spectrum disorders: the clinical validity of two measures presuming a continuum of social communication skills. J Autism Dev Disord. 2011;41:66–72. doi: 10.1007/s10803-010-1024-9.
    1. Corsello C, Hus V, Pickles A, Risi S, Cook EH, Jr, Leventhal BL, et al. Between a ROC and a hard place: decision making and making decisions about using the SCQ. J Child Psychol Psychiatry. 2007;48:932–40. doi: 10.1111/j.1469-7610.2007.01762.x.
    1. Bishop DV, Norbury CF. Exploring the borderlands of autistic disorder and specific language impairment: a study using standardised diagnostic instruments. J Child Psychol Psychiatry. 2002;43:917–29. doi: 10.1111/1469-7610.00114.
    1. Frye RE, Tippett M, Delhey L, Slattery J. Test-retest reliability and validity of the autism symptoms questionnaire. N Am J Med Sci. 2015;8:149–53.
    1. Frye RE, Slattery J, Delhey L, Furgerson B, Strickland T, Tippett M, et al. Folinic acid improves verbal communication in children with autism and language impairment: a randomized double-blind placebo-controlled trial. Mol Psychiatry. 2018;23:247–56. doi: 10.1038/mp.2016.168.
    1. Kaat AJ, Lecavalier L, Aman MG. Validity of the aberrant behavior checklist in children with autism spectrum disorder. J Autism Dev Disord. 2014;44:1103–16. doi: 10.1007/s10803-013-1970-0.
    1. Hill J, Powlitch S, Furniss F. Convergent validity of the aberrant behavior checklist and behavior problems inventory with people with complex needs. Res Dev Disabil. 2008;29:45–60. doi: 10.1016/j.ridd.2006.10.002.
    1. Rojahn J, Aman MG, Matson JL, Mayville E. The Aberrant Behavior Checklist and the Behavior Problems Inventory: convergent and divergent validity. Res Dev Disabil. 2003;24:391–404. doi: 10.1016/S0891-4222(03)00055-6.
    1. Kirby DM, Thorburn DR, Turnbull DM, Taylor RW. Biochemical assays of respiratory chain complex activity. Methods Cell Biol. 2007;80:93–119. doi: 10.1016/S0091-679X(06)80004-X.
    1. Burger BJ, Rose S, Bennuri SC, Gill PS, Tippett ML, Delhey L, et al. Autistic siblings with novel mutations in two different genes: insight for genetic workups of autistic siblings and connection to mitochondrial dysfunction. Front Pediatr. 2017;5:219. doi: 10.3389/fped.2017.00219.
    1. Jugé R, Breugnot J, Da Silva C, Bordes S, Closs B, Aouacheria A. Quantification and characterization of UVB-induced mitochondrial fragmentation in normal primary human keratinocytes. Sci Rep. 2016;6:35065. doi: 10.1038/srep35065.
    1. Lionnard L et al. Analyse des patrons de structuration et de distribution mitochondriale à des échelles subcellulaires locales ou globales. In: 10th Symposium de Morphométrie et Evolution des Formes Conference Bordeaux, France; 2018.
    1. Chajra H et al. An innovative strategy for quantitative analysis and visualization of mitochondrial organization, dynamics and activity in live skin cells. Milan, Italy: International Federation of Societies of Cosmetic Chemists; 2019.
    1. Cohen J. Statistical power analysis for the behavioral sciences. 2nd edn. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
    1. Rose S, Melnyk S, Pavliv O, Bai S, Nick TG, Frye RE, et al. Evidence of oxidative damage and inflammation associated with low glutathione redox status in the autism brain. Transl Psychiatry. 2012;2:e134. doi: 10.1038/tp.2012.61.
    1. Rose S, Niyazov DM, Rossignol DA, Goldenthal M, Kahler SG, Frye RE. Clinical and molecular characteristics of mitochondrial dysfunction in autism spectrum disorder. Mol Diagn Ther. 2018;22:571–93. doi: 10.1007/s40291-018-0352-x.
    1. Rose S, Melnyk S, Trusty TA, Pavliv O, Seidel L, Li J, et al. Intracellular and extracellular redox status and free radical generation in primary immune cells from children with autism. Autism Res Treat. 2012;2012:986519.
    1. Picard M, Zhang J, Hancock S, Derbeneva O, Golhar R, Golik P, et al. Progressive increase in mtDNA 3243A>G heteroplasmy causes abrupt transcriptional reprogramming. Proc Natl Acad Sci USA. 2014;111:E4033–4042. doi: 10.1073/pnas.1414028111.
    1. Vandewalle J, Bauters M, Van Esch H, Belet S, Verbeeck J, Fieremans N, et al. The mitochondrial solute carrier SLC25A5 at Xq24 is a novel candidate gene for non-syndromic intellectual disability. Hum Genet. 2013;132:1177–85. doi: 10.1007/s00439-013-1322-3.
    1. Licznerski P, Park HA, Rolyan H, Chen R, Mnatsakanyan N, Miranda P, et al. ATP synthase c-subunit leak causes aberrant cellular metabolism in fragile X syndrome. Cell. 2020;182:1170–85. doi: 10.1016/j.cell.2020.07.008.
    1. Ebrahimi-Fakhari D, Saffari A, Wahlster L, Sahin M. Using tuberous sclerosis complex to understand the impact of MTORC1 signaling on mitochondrial dynamics and mitophagy in neurons. Autophagy. 2017;13:754–6. doi: 10.1080/15548627.2016.1277310.
    1. Hwang SK, Lee JH, Yang JE, Lim CS, Lee JA, Lee YS, et al. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation. Mol Brain. 2016;9:56. doi: 10.1186/s13041-016-0222-6.
    1. Kilincaslan A, Kok BE, Tekturk P, Yalcinkaya C, Ozkara C, Yapici Z. Beneficial effects of everolimus on autism and attention-deficit/hyperactivity disorder symptoms in a group of patients with tuberous sclerosis complex. J Child Adolesc Psychopharmacol. 2017;27:383–8. doi: 10.1089/cap.2016.0100.
    1. Mizuguchi M, Ikeda H, Kagitani-Shimono K, Yoshinaga H, Suzuki Y, Aoki M, et al. Everolimus for epilepsy and autism spectrum disorder in tuberous sclerosis complex: EXIST-3 substudy in Japan. Brain Dev. 2019;41:1–10. doi: 10.1016/j.braindev.2018.07.003.
    1. Overwater IE, Rietman AB, Mous SE, Bindels-de Heus K, Rizopoulos D, Ten Hoopen LW, et al. A randomized controlled trial with everolimus for IQ and autism in tuberous sclerosis complex. Neurology. 2019;93:e200–e209. doi: 10.1212/WNL.0000000000007749.
    1. Feng C, Chen Y, Zhang Y, Yan Y, Yang M, Gui H, et al. PTEN regulates mitochondrial biogenesis via the AKT/GSK-3beta/PGC-1alpha pathway in autism. Neuroscience. 2021;465:85–94. doi: 10.1016/j.neuroscience.2021.04.010.
    1. Bam S, Buchanan E, Mahony C, O’Ryan C. DNA methylation of PGC-1alpha is associated with elevated mtDNA copy number and altered urinary metabolites in autism spectrum disorder. Front Cell Dev Biol. 2021;9:696428. doi: 10.3389/fcell.2021.696428.
    1. Mirza R, Sharma B. A selective peroxisome proliferator-activated receptor-gamma agonist benefited propionic acid induced autism-like behavioral phenotypes in rats by attenuation of neuroinflammation and oxidative stress. Chem Biol Interact. 2019;311:108758. doi: 10.1016/j.cbi.2019.108758.
    1. Mirza R, Sharma B. Beneficial effects of pioglitazone, a selective peroxisome proliferator-activated receptor-gamma agonist in prenatal valproic acid-induced behavioral and biochemical autistic like features in Wistar rats. Int J Dev Neurosci. 2019;76:6–16. doi: 10.1016/j.ijdevneu.2019.05.006.
    1. Kirsten TB, Casarin RC, Bernardi MM, Felicio LF. Pioglitazone abolishes cognition impairments as well as BDNF and neurotensin disturbances in a rat model of autism. Biol Open. 2019;10:8..
    1. Boris M, Kaiser CC, Goldblatt A, Elice MW, Edelson SM, Adams JB, et al. Effect of pioglitazone treatment on behavioral symptoms in autistic children. J Neuroinflammation. 2007;4:3. doi: 10.1186/1742-2094-4-3.
    1. Capano L, Dupuis A, Brian J, Mankad D, Genore L, Hastie Adams R, et al. A pilot dose finding study of pioglitazone in autistic children. Mol Autism. 2018;9:59. doi: 10.1186/s13229-018-0241-5.
    1. Ghaleiha A, Rasa SM, Nikoo M, Farokhnia M, Mohammadi MR, Akhondzadeh S. A pilot double-blind placebo-controlled trial of pioglitazone as adjunctive treatment to risperidone: effects on aberrant behavior in children with autism. Psychiatry Res. 2015;229:181–7. doi: 10.1016/j.psychres.2015.07.043.
    1. Frye RE, Rose S, Slattery J, MacFabe DF. Gastrointestinal dysfunction in autism spectrum disorder: the role of the mitochondria and the enteric microbiome. Micro Ecol Health Dis. 2015;26:27458.
    1. Takuma K, Hara Y, Kataoka S, Kawanai T, Maeda Y, Watanabe R, et al. Chronic treatment with valproic acid or sodium butyrate attenuates novel object recognition deficits and hippocampal dendritic spine loss in a mouse model of autism. Pharm Biochem Behav. 2014;126:43–49. doi: 10.1016/j.pbb.2014.08.013.
    1. Kratsman N, Getselter D, Elliott E. Sodium butyrate attenuates social behavior deficits and modifies the transcription of inhibitory/excitatory genes in the frontal cortex of an autism model. Neuropharmacology. 2016;102:136–45. doi: 10.1016/j.neuropharm.2015.11.003.
    1. Macfabe DF. Short-chain fatty acid fermentation products of the gut microbiome: implications in autism spectrum disorders. Microb Ecol Health Dis. 2012;23:19260..
    1. Frye RE, James SJ. Metabolic pathology of autism in relation to redox metabolism. Biomark Med. 2014;8:321–30. doi: 10.2217/bmm.13.158.

Source: PubMed

3
Suscribir